Bubendorf, Switzerland (3 February 2023) – Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has opened a state-of-the-art facility in Saint-Beauzire, France.

The new site is dedicated to the custom development and production of sterile injectable drug products. Built on newly acquired land located 7km from an existing CARBOGEN AMCIS site in Riom, the new...

Bubendorf, Switzerland (Septembre 29, 2022) – Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that its site in Vionnaz, Switzerland has successfully completed a Swissmedic inspection performed by Regional Medicines Inspectorate of Western Switzerland (ISOPTh).

The two-day inspection took place from September 20th to 21th, 2022 and was undertaken by an inspector of Regional Medicines Inspectorate of Western Switzerland...

BUBENDORF, Switzerland (July 21, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today the appointment of François Baduel as Vice President of Business Development, Sales & Marketing.

In his new role, François Baduel will lead the company’s overall sales and marketing operations. He will report directly to Pascal Villemagne, Chief Executive Officer,...

BUBENDORF, Switzerland (March 31, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that Pascal Villemagne has been named Chief Executive Officer, effective first of April

In his new role, Pascal Villemagne will be leading CARBOGEN AMCIS and its nine sites around the world. He will report to Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd., CARBOGEN AMCIS’ parent company. Villemagne, who has served as Vice President of Sales...

Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte...

MEYLAN, France, BUBENDORF, Switzerland, (November 3rd, 2021) - NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and Drug Products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.

CARBOGEN AMCIS just released the fifth batch of AGuIX Drug Product since inception of the company. The release of this 3.7 kg batch...

BUBENDORF, Switzerland (27 October 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces the completion of a U.S. Food and Drug Administration (FDA) inspection at the site in Aarau, Switzerland.

The pre-approval FDA paper inspection for an intermediate product from a customer was conducted from 17 August - 15 September 2021. By receiving the result in October 2021 the inspection was concluded successfully with no findings, confirming that...

BUBENDORF, Switzerland (27 Aug 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co-investment agreement with one of its key European customers.

The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and is following a previous investment of CHF 6 million.

The recent...

BUBENDORF, Switzerland (April 29th, 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long standing Japan based customer to build  a site extension at the Bubendorf site in Switzerland.  

The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will...

Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN...

BUBENDORF, Switzerland (October 11th, 2017) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced today that its Bubendorf, Switzerland API manufacturing site has successfully completed a routine U.S. Food and Drug Administration (FDA) inspection.

The cGMP (current Good Manufacturing Practices) Audit was completed over five days, from September 4th to 8th, 2017. The inspection consisted of an analysis of all Quality Systems,...

BUBENDORF, Switzerland (July 21st, 2017) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced the renewal of cGMP certificates, and the successful completion of Swissmedic inspections at three of its sites. 

Swissmedic conducted inspections (general surveillance audits) of three of CARBOGEN AMCIS' facilities – Bubendorf, Aarau and Neuland – in late April and early May, 2017. No significant concerns were...

AHMEDABAD, INDIA, August 11, 2016 – Dishman Pharmaceuticals and Chemicals Ltd (DPCL), leading outsourcing partner for the global pharmaceutical industry, today marked the 10-year anniversary of its acquisition of CARBOGEN AMCIS. A significant milestone of growth and development of Indian-Swiss business relations.
 
CARBOGEN AMCIS (headquarters in Bubendorf, Switzerland) and Dishman Pharmaceuticals and Chemicals Ltd (headquarters in Ahmedabad, India) are both suppliers of complex services and products for the global pharmaceutical industry....

BUBENDORF, Switzerland (July 13th, 2016) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced, after reception of the Establishment Inspection Report (EIR), that two of its Swiss sites have successfully completed a U.S. Food and Drug Administration (FDA) inspection.

The Pre-Approval Inspections (PAIs) have been completed by an FDA inspector over four days: October 19-20, 2015 in Aarau and October 21 – 22, 2015 in Neuland. The...

BUBENDORF, Switzerland (May 31st, 2016) — CARBOGEN AMCIS, the Swiss-based company offering process development and manufacturing of Active Pharmaceutical Ingredient (API) to the pharmaceutical industry, has announced the extension of its operations in Bubendorf.
 
On May 26th, 2016, we (CARBOGEN AMCIS) have undersigned the acquisition of the land and buildings of GEA Pharma Systems AG in Bubendorf, Hauptstrasse 145. The acquisition close to our current headquarters will become effective on Jan. 1st, 2017.
 
Located on 5’200 m²...

CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced a successful inspection by Swissmedic of its recently acquired site in Vionnaz, Switzerland.

The site has been inspected by Swissmedic and by the U.S. Food and Drug Administration (FDA) in the past and the re-audit is due to the change of ownership. The two-and-a-half-day audit covered the Quality System related to development and manufacture of highly potent APIs at the Vionnaz facility, including Analytical and...

CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced that Mark C. Griffiths, global chief executive officer of Dishman and CARBOGEN AMCIS, has joined the board of directors of Dishman Pharmaceuticals and Chemicals Ltd.

The appointment was made public by Shri Arpit J. Vyas, managing director,Dishman Pharmaceuticals and Chemicals Ltd.“We are excited to welcome Mark to the board of Dishman. Mark’s leadership at...

CARBOGEN AMCIS, the Swiss-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced plans to take over operations of a high-containment facility located in Vionnaz, Switzerland, 70 kilometers East of Geneva:

CARBOGEN AMCIS │ Route du Simplon 24 │ CH-1895 Vionnaz │ Switzerland

The high potency facility in Vionnaz opened in December 2005 and was formerly managed by Bachem AG as an integrated part of their site in Vionnaz....

To meet rising demand for highly potent active pharmaceutical ingredients (APIs) spurred by the growing targeted therapy approach in the treatment of diseases, in particular oncology, Switzerland-based CARBOGEN AMCIS AG today announced that it has completed a capital investment project to upgrade its high potency capabilities. An industry leader in the production of high potency APIs, CARBOGEN AMCIS offers drug developers the full range of high potency services, from development, manufacturing and chromatography, to antibody drug conjugates (ADCs), fill &...